Work

First‐Line Treatment of Icaritin and Thalidomide in a Patient With Hepatocellular Carcinoma With PR : A Case Report

Year: 2025

Type: article

Abstract: BACKGROUND: Hepatocellular carcinoma (HCC) remains a significant global health burden, with unmet clinical needs despite the availability of multiple therapeutic options. CASE: We present the case of an 85-year-old male diagnosed with HCC and bilateral lung metastases following hepatectomy. The patient responded favorably to treatment with icaritin and thalidomide, which resulted in a reduction in alpha-fetoprotein (AFP) levels and tumor size. This treatment achieved partial remission, with a progression-free survival (PFS) of 24 months and an overall survival (OS) of 33 months. Unfortunately, the patient ultimately passed away due to a cerebral infarction unrelated to cancer progression. CONCLUSION: This case underscores the potential of icaritin as a therapeutic option for HCC patients with compromised health status. The combination of icaritin and thalidomide demonstrated promising efficacy in this real-world scenario. Multidisciplinary combination treatment strategies incorporating icaritin merit further exploration, given its immunomodulatory effects and favorable safety profile.

Source: Cancer Reports

DOI: 10.1002/cnr2.70136

Authors: Zaiyong Jin, Fei Zhou, Zhuo Wang, Hongji Li

Institution: Jilin City Central Hospital

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,280